Charles Schwab Investment Management Inc. Sells 1,184 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

Charles Schwab Investment Management Inc. lowered its position in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 0.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 567,409 shares of the company’s stock after selling 1,184 shares during the period. Charles Schwab Investment Management Inc. owned 0.73% of Travere Therapeutics worth $7,938,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Creative Planning raised its stake in shares of Travere Therapeutics by 4.3% in the third quarter. Creative Planning now owns 23,938 shares of the company’s stock valued at $335,000 after acquiring an additional 995 shares during the last quarter. Forefront Analytics LLC increased its holdings in shares of Travere Therapeutics by 10.2% in the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock valued at $109,000 after purchasing an additional 1,237 shares in the last quarter. Rice Hall James & Associates LLC increased its holdings in shares of Travere Therapeutics by 3.8% in the second quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company’s stock valued at $626,000 after purchasing an additional 2,774 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Travere Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock valued at $240,000 after purchasing an additional 2,948 shares in the last quarter. Finally, CWM LLC increased its holdings in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock valued at $70,000 after purchasing an additional 3,065 shares in the last quarter.

Insider Activity

In other Travere Therapeutics news, CAO Sandra Calvin sold 12,090 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $18.30, for a total transaction of $221,247.00. Following the transaction, the chief accounting officer now owns 54,927 shares in the company, valued at $1,005,164.10. The trade was a 18.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Gary A. Lyons sold 40,000 shares of the business’s stock in a transaction on Friday, October 4th. The shares were sold at an average price of $14.73, for a total transaction of $589,200.00. Following the transaction, the director now owns 51,000 shares in the company, valued at $751,230. This trade represents a 43.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,090 shares of company stock valued at $1,372,847 in the last 90 days. 3.75% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of analysts recently weighed in on TVTX shares. Wedbush raised their price target on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Barclays lifted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $9.00 to $27.00 in a report on Monday, October 21st. Bank of America lifted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Finally, Guggenheim lifted their target price on shares of Travere Therapeutics from $23.00 to $41.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $22.62.

Travere Therapeutics Price Performance

Shares of Travere Therapeutics stock opened at $18.75 on Wednesday. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.33. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -4.12 and a beta of 0.69. The company has a fifty day moving average of $17.86 and a 200-day moving average of $12.50. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.01. The business had revenue of $62.90 million during the quarter, compared to analysts’ expectations of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm’s revenue for the quarter was up 69.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.17) EPS. Equities research analysts expect that Travere Therapeutics, Inc. will post -3.94 EPS for the current year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.